Literature DB >> 22289917

Consequences of heat shock protein 72 (Hsp72) expression and activity on stress-induced apoptosis in CD30+ NPM-ALK+ anaplastic large-cell lymphomas.

P Bonvini1, E Zorzi, L Mussolin, M Pillon, C Romualdi, M Peron, E S G d'Amore, L Lamant, A Rosolen.   

Abstract

Understanding the mechanisms that control stress-induced apoptosis is critical to explain how tumours respond to treatment, as cancer cells frequently escape drug toxicity by regulating stress response through heat shock protein (HSP) expression. The overexpression of Hsp72, in particular, results in increased incidence of cell transformation, and correlates with poor prognosis in a wide range of cancers. We have shown that Hsp72 assists folding of oncogenic NPM-ALK kinase in anaplastic large-cell lymphomas (ALCLs), but its role in the maintenance of the malignant phenotype remains uncertain. Therefore, we assessed Hsp72 expression in ALCLs, investigating more in detail the mechanisms that regulate its status and activity. We found that Hsp72 is unique among the HSPs involved in tumourigenesis to be overexpressed in ALK(+) tumours and cell lines and to be induced by stress. Different from other HSPs, Hsp72 prevents cell injury, Bax activation and death by apoptosis in ALK(+) cells, acting both upstream and downstream of mitochondria. Conversely, Hsp72 is underexpressed in ALK(-) ALCL cells, and it is unable to protect cells from apoptosis under stress. Moreover, when Hsp72 expression is reduced following NPM-ALK inhibition, lymphoma cells undergo apoptosis, demonstrating the importance of Hsp72 in regulating ALCL stress response and drug sensitivity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22289917     DOI: 10.1038/leu.2011.367

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  2 in total

1.  ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2.

Authors:  Saskia A G M Cillessen; Nathalie J Hijmering; Laura M Moesbergen; Wim Vos; Sue Ellen Verbrugge; Gerrit Jansen; Otto J Visser; Joost J Oudejans; Chris J L M Meijer
Journal:  Haematologica       Date:  2015-05-14       Impact factor: 9.941

2.  ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.

Authors:  Federica Lovisa; Giorgio Cozza; Andrea Cristiani; Alberto Cuzzolin; Alessandro Albiero; Lara Mussolin; Marta Pillon; Stefano Moro; Giuseppe Basso; Angelo Rosolen; Paolo Bonvini
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.